Randomized controlled trialHuman
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Diabetes, obesity & metabolism, 2022 Aug. Wilding JPH, Batterham RL, Davies M and 12 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Diabetes, obesity & metabolism
Published
2022 Aug
PubMed
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultCardiovascular DiseasesDiabetes MellitusGlucagon-Like PeptidesHumansWeight GainSemaglutide
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page